Dyadic Updates Market on COVID-19 Initiatives

* C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved * Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators * Record Expression Level of C1 SARS-CoV-2 RBD Antigen (3 g/l in 5 days) * Non-Exclusive Technology Usage Agreement with Epygen Biotech of India

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here